The Cancer Researcher
  • Home
  • About
  • The Cancer Researcher Podcast
  • #KeepResearchCurious
No Result
View All Result
  • Home
  • About
  • The Cancer Researcher Podcast
  • #KeepResearchCurious
No Result
View All Result
The Cancer Researcher
No Result
View All Result

AI-driven PD-L1 scoring in lung cancer: an interview with Liesbeth Hondelink

August 14, 2025
‘Science in Motion: Navigating Transitions’: EACR Science Communication Prize 2023

Liesbeth’s research focuses on developing a deep learning AI algorithm, or an AI model, for the automated scoring of PD-L1 in non-small cell lung cancer (NSCLC) and to then validate and generalize the AI model across different laboratories in the Netherlands. The AI model is trained to identify tumor cells in different tissues and to then calculate the percentage of tumors positive for PD-L1, a vital piece of information in determining the best course of immunotherapy in some cases of NSCLC.

Can you please describe your project utilizing AI?

We created an AI model, a deep learning algorithm, with the Aiforia Create software for PD-L1 scoring in NSCLC histology earlier and are now aiming to validate this AI model in other laboratory workups as well, including different antibodies and scanners. We will describe the steps that are needed for adapting an existing AI model to a new, local laboratory workup (domain adaptation).

This is a very relevant research question because many algorithms exist nowadays, but very few are reliable in new circumstances, especially in immunohistochemistry where there is great variation between laboratories. There are no clear guidelines on how to adapt an existing pathology algorithm to a new workup yet.

What do you think makes this project unique?

As far as I know, this is the first multi-centre domain adaptation study for medical image analysis. It answers a relevant question: how does one start using existing algorithm in a previously unseen (by the AI) workflow?

Why did you decide to use the Aiforia software for this?

Easy-to-use, powerful and it permits quick training methods!

How much training data did you need to train the AI model?

74 images were used for designing the base algorithm. For each workup we will use 50 additional slides as potential training data, and 50 slides as validation data.

What was the AI model trained to detect and analyze?

Tissue: high quality tissue (segmentation). Tumor: tumor vs other tissue (segmentation), within the high-quality tissue. Positivity: PD-L1 positive VS negative tumor nuclei (object detection), within the tumor. The outcome is the percentage of PD-L1 positive tumor nuclei.

How did the AI model perform?

For the base AI model (not generalized to the other workups yet): Error % Less than 0.5% for all semantic segmentation layers and about 9% error for object detection. On a whole slide level the agreement to the gold standard is approximately 80%, which is equally accurate as pathologists themselves doing the task.

What was it like working with the Aiforia software and team?

It was a good experience! The scientists and support team at Aiforia respond very quickly and have a lot of technical expertise. It has been very easy to work with Aiforia, I especially like that you don’t have to worry about AI hyper-parameters and storage issues, but can focus on annotations and AI model performance. I also liked the Annotation Assistant very much, it speeds up annotating significantly, by proposing training regions and annotations.

This article was originally published by Aiforia as a blog post on their website, and has been republished here with permission.

Find out more about Aiforia’s AI for image analysis software.

To read more about research from The Pathology Department at Leiden University Medical Center, click here.

Tags: AIAiforiaindustryinterviewLung cancer

Related Posts

“The free registration allowed me to attend a conference that would otherwise have been difficult to access”

“The free registration allowed me to attend a conference that would otherwise have been difficult to access”

November 10, 2026

The EACR often has opportunities to offer a free registration for one or more EACR members to attend an external conference not associated with the EACR....

Beyond the Award: The Rising Star Award Recipients

Beyond the Award: The Rising Star Award Recipients

November 4, 2026

The EACR-Mark Foundation-Pezcoller Foundation Rising Star Award is open to EACR members with an unfunded Score ‘A’ cancer-related project from the previous year's ERC Starting Grant...

EACR-funded workshops help early-career researchers develop skills beyond the lab

EACR-funded workshops help early-career researchers develop skills beyond the lab

November 2, 2026

In September 2026, the EACR provided 68 funded places to EACR members across three dedicated workshops for early-career researchers, delivered virtually by EMBO Solutions. Focusing on...

The Cancer Researcher EACR logo

About Us

The Cancer Researcher is an online magazine for the cancer research community from the European Association for Cancer Research.

The EACR, a registered charity, is a global community for those working and studying in cancer research. Our mission is “The advancement of cancer research for the public benefit: from basic research to prevention, treatment and care.”

Advertisement Advertisement Advertisement
ADVERTISEMENT

RECENT POSTS

“The free registration allowed me to attend a conference that would otherwise have been difficult to access”
Community

“The free registration allowed me to attend a conference that would otherwise have been difficult to access”

November 10, 2026
Beyond the Award: The Rising Star Award Recipients
Career

Beyond the Award: The Rising Star Award Recipients

November 4, 2026
The Cancer Researcher

© 2025 EACR

Navigate site

  • About
  • Privacy
  • Main EACR website

Follow us

No Result
View All Result
  • Home
  • About
  • The Cancer Researcher Podcast
  • #KeepResearchCurious

© 2025 EACR